Search
IL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalNatural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Synonyms: IL15-NK CellLetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage.
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … [L54748] Developed through a collaboration involving the Global Antibiotic Research and Development Partnership (GARDP), zoliflodacin received approval from the U.S.
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil.
Human papillomavirus type 33 L1 capsid protein antigen
go.drugbank.com/drugs/DB10311ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONHuman papillomavirus type 45 L1 capsid protein antigen
go.drugbank.com/drugs/DB10312ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONHuman papillomavirus type 58 L1 capsid protein antigen
go.drugbank.com/drugs/DB10314ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONProguanil
go.drugbank.com/drugs/DB01131ApprovedProguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. … It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedIt was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]